Ignite Creation Date:
2024-05-05 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 9:39 AM
Study NCT ID:
NCT00582634
Status:
COMPLETED
Last Update Posted:
2019-11-19
First Post:
2007-12-19
Brief Title:
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
Phase II Study of Adjuvant Cisplatin and Docetaxel in Non-small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer
To evaluate the time to progression and overall survival
To evaluate toxicities of this chemotherapy combination in the adjuvant setting
To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen
To evaluate the time to progression and overall survival
To evaluate toxicities of this chemotherapy combination in the adjuvant setting
To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SMPHMEDICINE | OTHER | UW Madison | None |
| CO04503 | OTHER | None | None |
| H-2004-0248 | OTHER | None | None |
| A534260 | OTHER | None | None |